Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Choroidal Neovascularization - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Choroidal Neovascularization - Pipeline Review, H2 2016', provides an overview of the Choroidal Neovascularization pipeline landscape. The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization - The report reviews pipeline therapeutics for Choroidal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Choroidal Neovascularization therapeutics and enlists all their major and minor projects - The report assesses Choroidal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Choroidal Neovascularization Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Choroidal Neovascularization Overview 7 Therapeutics Development 8 Pipeline Products for Choroidal Neovascularization - Overview 8 Pipeline Products for Choroidal Neovascularization - Comparative Analysis 9 Choroidal Neovascularization - Therapeutics under Development by Companies 10 Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 11 Choroidal Neovascularization - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Choroidal Neovascularization - Products under Development by Companies 15 Choroidal Neovascularization - Products under Investigation by Universities/Institutes 16 Choroidal Neovascularization - Companies Involved in Therapeutics Development 17 F. Hoffmann-La Roche Ltd. 17 Formycon AG 18 Genentech, Inc. 19 Graybug Vision Inc 20 Mabion SA 21 Navigen Pharmaceuticals, Inc. 22 Noxxon Pharma AG 23 Promedior, Inc. 24 Choroidal Neovascularization - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 ACX-107 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 aflibercept biosimilar - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AP-202 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Doxarubicin Pegylated - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MAb-30D8 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 NAV-2729 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 NM-9405 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 NOXD-20 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 PRM-167 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ranibizumab - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ranibizumab biosimilar - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 RG-7716 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Choroidal Neovascularization - Dormant Projects 58 Choroidal Neovascularization - Discontinued Products 60 Choroidal Neovascularization - Product Development Milestones 61 Featured News & Press Releases 61 Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 61 Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 61 May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for Choroidal Neovascularization, H2 2016 8 Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 17 Choroidal Neovascularization - Pipeline by Formycon AG, H2 2016 18 Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2016 19 Choroidal Neovascularization - Pipeline by Graybug Vision Inc, H2 2016 20 Choroidal Neovascularization - Pipeline by Mabion SA, H2 2016 21 Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 22 Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2016 23 Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Choroidal Neovascularization - Dormant Projects, H2 2016 58 Choroidal Neovascularization - Dormant Projects (Contd..1), H2 2016 59 Choroidal Neovascularization - Discontinued Products, H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.